ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2285

Safety and Efficacy of Rilonacept in Patients with Deficiency of Interleukin-1 Receptor Antagonist (DIRA)

Dawn C. Chapelle Neal1, Adriana Almeida de Jesus2, Yan Huang3, Yin Liu3, Raphaela Goldbach-Mansky3 and Gina Montealegre4, 1National Institutes of Health, NIAMS/NIH, Bethesda, MD, 2Translational Autoinflammatory Disease Section, NIAMS/NIH, Bethesda, MD, 3Translational Autoinflammatory Diseases Section, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 4Office of the Clinical Director, NIAMS/NIH, Bethesda, MD

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Autoinflammatory Disease

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Systemic Juvenile Idiopathic Arthritis, Spondyloarthropathy and Miscellaneous Pediatric Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: Deficiency of interleukin-1 receptor antagonist (DIRA) is a neonatal-onset autoinflammatory syndrome caused by recessive mutations in IL1RN gene, the gene encoding the interleukin-1-receptor antagonist. It is clinically characterized by a perinatal-onset of pustular dermatosis, aseptic multifocal osteomyelitis, and marked elevation of acute phase reactants. In our treated patients, IL-1 blockade with daily anakinra leads to rapid and complete resolution of symptoms and normalization of the acute phase reactants. There is a need, however, for longer acting IL-1 blocking agents that are more convenient to administer and are less likely to cause injection site reactions.  

Objectives: The primary objective of this study is to assess the ability of rilonacept to achieve/maintain remission in patients with DIRA who have shown response to anakinra. The secondary objective is to assess the safety of rilonacept in DIRA patients, and to assess its ability to prevent new organ damage. 

Methods: Patients with a genetically confirmed diagnosis of DIRA and an adequate response to anakinra are eligible for the study. Per protocol, anakinra was discontinued 24 hours prior to first dose of study medication.  A loading dose of rilonacept of 4.4 mg/kg/ week was given and then decreased to a maintenance dose of 2.2 mg/kg/week. Patients who met flare criteria were subsequently escalated to 4.4 mg/kg/week with the option to increase to 6.6 mg/kg/week if needed. Diary and Dermatology scores in addition to ESR and CRP were collected at each visit.  Paired t-test analyses were used to compare baseline and the most recent clinic visit data.

Results: Six Caucasian patients have been enrolled, 50% male, with a mean age of 4.8 years SD (±1.3). All patients were in remission on anakinra (diary score 0) with a mean dosage of 3.21 mg/kg/day SD (±0.48). The mean follow-up time has been 4.5 months. The diary scores have increased to 0.09 at the last visit, reflecting the onset of nail changes in one patient.  All patients (except one) required an escalation in dosage from 2.2 mg/kg/week to 4.4 mg/kg/week due to a transient increase in micropustular lesions mostly in hyperkeratotic areas of the skin (elbow and knee). The micropustular lesions lead to the increase in dermatology scores from 1.3 to 3.2. Despite the mild skin lesions, no new bone lesions were detected and the acute phase reactants have decreased from baseline. No SAE’s have occurred and four adverse events have been reported.

Conclusion: Preliminary data in six DIRA patients suggest that doses of rilonacept at 4.4 mg/kg/week are required to achieve remission. Rilonacept treatment provides increased quality of life due to weekly injections. Long acting IL-1 inhibition with rilonacept seems to be a viable option in the treatment of DIRA.


Disclosure:

D. C. Chapelle Neal,
None;

A. Almeida de Jesus,
None;

Y. Huang,
None;

Y. Liu,
None;

R. Goldbach-Mansky,

Regeneron,

2;

G. Montealegre,

Regeneron,

2.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/safety-and-efficacy-of-rilonacept-in-patients-with-deficiency-of-interleukin-1-receptor-antagonist-dira/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.